Panbela Therapeutics, Inc. PBLA
Set alert
0.01 USD 0.00 0.00%
At close · Oct 29
0.02 Day range 0.02
0.0001 52-week range 0.05
- YTD
- +5,450.00%
- 1 year
- +5,450.00%
- Open
- 0.02
- Prev close
- 0.0111
- Mkt cap
- 53.89K
- Vol
- 1.01K
- Avg vol
- 756
- EPS
- -1,915.86
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.02
- High
- 0.02
- Forward P/E
- -0.02
- Beta
- 0.82
- Short ratio
- 0.07
- Inst. own
- 0.60%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 5.07
- 200-d avg
- 30.69
- 1y target
- 410.00
2Y chart
Events in this range
- Nov 14, 2024Earnings: -1.48; estimate 0; surprise —%
Signals (95)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 26, 2026 | 6 days ago |
| SMA: Bullish | Oct 26, 2026 | 6 days ago |
| MACD: Buy Signal | Oct 26, 2026 | 6 days ago |
| RSI: Oversold | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 8, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| SMA: Bullish | Sep 16, 2026 | 1 month ago |
| SMA: Bullish | Sep 16, 2026 | 1 month ago |
| RSI: Overbought | Sep 16, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| RSI: Oversold | Aug 10, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 24, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| RSI: Oversold | Jun 24, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | May 29, 2026 | 5 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| RSI: Overbought | May 29, 2026 | 5 months ago |
| SMA: Bearish | May 5, 2026 | 6 months ago |
| MACD: Sell Signal | May 5, 2026 | 6 months ago |
| SMA: Bullish | Apr 20, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 2, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 6, 2026 | 8 months ago |
| SMA: Bullish | Feb 27, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 27, 2026 | 8 months ago |
| RSI: Overbought | Feb 27, 2026 | 8 months ago |
| SMA: Bearish | Feb 26, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Feb 20, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 20, 2026 | 8 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 14, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 8, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| SMA: Bullish | Jan 2, 2026 | 10 months ago |
| MACD: Buy Signal | Jan 2, 2026 | 10 months ago |
| MACD: Sell Signal | Dec 18, 2025 | 10 months ago |
| SMA: Bearish | Dec 16, 2025 | 10 months ago |
| SMA: Bullish | Dec 12, 2025 | 10 months ago |
| SMA: Bearish | Dec 11, 2025 | 10 months ago |
| SMA: Bullish | Dec 4, 2025 | 11 months ago |
| SMA: Bearish | Dec 3, 2025 | 11 months ago |
| SMA: Bullish | Dec 2, 2025 | 11 months ago |
| RSI: Oversold | Oct 28, 2025 | 1 year ago |
| RSI: Oversold | Oct 20, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 8, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 2, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 25, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 8, 2025 | 1 year ago |
| RSI: Oversold | Sep 8, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 31, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 11, 2025 | 1 year ago |
| SMA: Bullish | Jul 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 10, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 17, 2025 | 1 year ago |
| SMA: Bearish | Jun 16, 2025 | 1 year ago |
| SMA: Bullish | Jun 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 11, 2025 | 1 year ago |
| SMA: Bearish | Jun 4, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| MACD: Buy Signal | May 28, 2025 | 1 year ago |
| MACD: Sell Signal | May 19, 2025 | 1 year ago |
| MACD: Buy Signal | May 8, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 28, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 22, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 20, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 14, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 12, 2025 | 1 year ago |
| SMA: Bullish | Mar 11, 2025 | 1 year ago |
| SMA: Bearish | Mar 6, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 6, 2025 | 1 year ago |
| SMA: Bullish | Mar 5, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 5, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 4, 2025 | 1 year ago |
| SMA: Bearish | Feb 28, 2025 | 1 year ago |
| SMA: Bullish | Feb 21, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 21, 2025 | 1 year ago |
| SMA: Bearish | Feb 5, 2025 | 1 year ago |
| SMA: Bullish | Feb 4, 2025 | 1 year ago |
| SMA: Bearish | Jan 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 15, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
Key statistics
- Market cap
- 2.33M
- Enterprise value
- 4.48M
- Trailing P/E
- 0.00
- Forward P/E
- -0.02
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -157.02
- Beta
- 0.82
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -12.34M
- Total cash
- 907.00K
- Total debt
- 5.19M
- Return on equity
- 0.00%
- Shares outstanding
- 3.48M
- Short % of float
- 3.07%
- 50-day average
- 5.07
- 200-day average
- 30.69
Analyst view
Consensus: buy
Buy
Price target (mean) 410.00 +3693593.7% upside
Now 0.0111
- Target (low)
- 320.00
- Target (mean)
- 410.00
- Target (high)
- 500.00
Next earnings
Consensus EPS estimate -24.34.
Financials — quick view
PBLA Revenue — quarterly 0
PBLA Net income — quarterly -7.83M
PBLA EPS — quarterly -54.00
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.48 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -2.07 | -1.47 | +0.60 | +28.99% |
| May 15, 2024 | Mar 1, 2024 | -1.23 | -2.28 | -1.05 | -85.37% |
| Mar 26, 2024 | Dec 1, 2023 | -24.34 | -65.90 | -41.56 | -170.75% |
| Nov 9, 2023 | Sep 1, 2023 | -41.20 | -53.80 | -12.60 | -30.58% |
| Aug 10, 2023 | Jun 1, 2023 | -94.20 | -159.00 | -64.80 | -68.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 23, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 9, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 1, 2023 | HC Wainwright & Co. | reit | — | Buy |
About Panbela Therapeutics, Inc.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
- Country
- United States
- Website
- panbela.com
News
- Leap Therapeutics (NASDAQ:LPTX) vs. Panbela Therapeutics (OTCMKTS:PBLA) Head-To-Head Analysis
- Panbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call Transcript
- Panbela Provides Business Update and Reports Q3 2024 Financial Results
- Panbela Therapeutics, Inc. (PBLA) Q2 2024 Earnings Call Transcript
- Panbela Provides Business Update and Reports Q2 2024 Financial Results
- Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
- Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
- Panbela Therapeutics, Inc. (NASDAQ:PBLA) to Post Q2 2024 Earnings of ($2.07) Per Share, HC Wainwright Forecasts
- Panbela Therapeutics, Inc. (PBLA) Q1 2024 Earnings Call Transcript
- Panbela Provides Business Update and Reports Q1 2024 Financial Results
Your note
Sign in to keep a note on PBLA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CULLEN MICHAEL T | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 3, 2022 | 0 |
| FRATAMICO ARTHUR R | Director | Stock Award(Grant) | May 24, 2021 | 9,615 |
| GAGNON SUZANNE | Director | Stock Gift | Apr 28, 2021 | 0 |
| GOLDMAN SACHS GROUP, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 7, 2023 | 0 |
| HORVATH SUSAN | Chief Financial Officer | Purchase | Jan 29, 2023 | 17,880 |
| JACOB JEFFREY E | Director | Stock Gift | Sep 11, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sabby Management, LLC | 7.97% | 235,819 | 542.38K | Jun 29, 2023 |
| Walleye Capital LLC | 3.20% | 94,536 | 217.43K | Jun 29, 2023 |
| Hudson Bay Capital Management Lp | 2.57% | 76,000 | 174.80K | Jun 29, 2023 |
| Tower Research Capital LLC (TRC) | 0.13% | 3,713 | 8.54K | Jun 29, 2023 |
| UBS Group AG | 0.03% | 823 | 1.89K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.14% | 4,248 | 9.77K | Jun 29, 2023 |